We are live on ! Find out more
MDGL icon

Madrigal Pharmaceuticals
MDGL

135 hedge funds and large institutions have $1.19B invested in Madrigal Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 50 increasing their positions, 31 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

131% more call options, than puts

Call options by funds: $79.4M | Put options by funds: $34.3M

61% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 31

17% more capital invested

Capital invested by funds: $1.01B → $1.19B (+$174M)

3.02% more ownership

Funds ownership: 58.36% → 61.37% (+3%)

0% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 23

1% less funds holding

Funds holding: 136 → 135 (-1)

Holders
135
Holders Change
-1
Holders Change %
-0.74%
% of All Funds
2.92%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.06%
New
23
Increased
50
Reduced
31
Closed
23
Calls
$79.4M
Puts
$34.3M
Net Calls
+$45.1M
Net Calls Change
-$34M

Top Buyers

1
AC
Armistice Capital
New York
+$52.8M
2
HM
HealthCor Management
New York
+$25.2M
3
MWNA
Marshall Wace North America
New York
+$17.6M
4
ACA
Avoro Capital Advisors
New York
+$10.6M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$5.59M

Top Sellers

1
JP Morgan Chase
JP Morgan Chase
New York
-$48.3M
2
Morgan Stanley
Morgan Stanley
New York
-$6.28M
3
Citigroup
Citigroup
New York
-$6.09M
4
AG
Artal Group
Luxembourg
-$4.35M
5
PC
Pier Capital
Connecticut
-$4.24M
Name Holding Trade Value Shares
Change 		Change in
Stake
CS
26
Candriam SCA
Luxembourg
$5.19M +$1.24M +10,000 +32%
Macquarie Group
27
Macquarie Group
Australia
$5.09M +$186K +1,500 +4%
AA
28
ALPS Advisors
Colorado
$4.66M +$200K +1,608 +5%
AG
29
Artal Group
Luxembourg
$4.38M -$4.35M -35,000 -50%
Fidelity Investments
30
Fidelity Investments
Massachusetts
$4.29M – – –
Adage Capital Partners
31
Adage Capital Partners
Massachusetts
$4.01M -$622K -5,000 -13%
Man Group
32
Man Group
United Kingdom
$3.99M -$3.63M -29,208 -48%
Rafferty Asset Management
33
Rafferty Asset Management
New York
$3.95M +$3.92M +31,511 New
PVAM
34
Pacific View Asset Management
California
$3.93M +$781K +6,286 +25%
JG
35
Jefferies Group
New York
$3.88M +$256K +2,057 +7%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$3.86M -$4.1K -33 -0.1%
RPAM
37
Rhenman & Partners Asset Management
Sweden
$3.41M +$3.38M +27,225 New
Bank of Montreal
38
Bank of Montreal
Ontario, Canada
$3.3M +$3.05M +24,553 +1,366%
Invesco
39
Invesco
Georgia
$3.23M +$3.21M +25,813 New
Point72 Asset Management
40
Point72 Asset Management
Connecticut
$2.6M -$4.01M -32,233 -61%
Marshall Wace
41
Marshall Wace
United Kingdom
$2.56M +$2.54M +20,462 New
Victory Capital Management
42
Victory Capital Management
Texas
$2.49M +$854K +6,870 +53%
UONDDL
43
University of Notre Dame du Lac
Indiana
$2.41M +$21.6K +174 +0.9%
TA
44
Teachers Advisors
New York
$2.36M +$76.9K +619 +3%
FAM
45
Fred Alger Management
New York
$2.3M -$24.2K -195 -1%
EU
46
Emory University
Georgia
$2.21M +$73.8K +594 +3%
MFG
47
Magnus Financial Group
New York
$2.18M +$2.16M +17,413 New
Dimensional Fund Advisors
48
Dimensional Fund Advisors
Texas
$2.16M +$1.19M +9,608 +125%
Deutsche Bank
49
Deutsche Bank
Germany
$2.06M -$868K -6,984 -30%
GC
50
Guggenheim Capital
Illinois
$2.03M -$202K -1,622 -9%
1
2
3 4 5

MDGL Hedge Fund Activity: Q1 2019 in Review

135 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q1 2019, worth a combined $1.19B — up 17% from $1.01B a quarter earlier.

Fund positioning in MDGL was balanced in Q1 2019: 23 funds opened new positions, 23 closed out, 50 added to existing stakes and 31 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $52.8M. The largest seller was JP Morgan Chase, cutting an estimated $48.3M.

  • 135 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q1 2019, down from 136 in Q4 2018.
  • Funds reported $1.19B of Madrigal Pharmaceuticals stock for Q1 2019, up 17% quarter-over-quarter.
  • 23 funds opened new Madrigal Pharmaceuticals positions in Q1 2019 and 23 closed out, a net change of 0 holders.
  • The largest Madrigal Pharmaceuticals buyer in Q1 2019 was Armistice Capital, an estimated $52.8M added.
  • The largest Madrigal Pharmaceuticals seller in Q1 2019 was JP Morgan Chase, an estimated $48.3M sold.

Based on aggregated 13F filings for Q1 2019.